Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H
Front Immunol. 2025; 15:1502721.
PMID: 39763650
PMC: 11701239.
DOI: 10.3389/fimmu.2024.1502721.
Majigoudra G, Duggal A, Chowdhury D, Koul A, Todi V, Roshan S
Ann Indian Acad Neurol. 2023; 26(4):441-446.
PMID: 37970285
PMC: 10645219.
DOI: 10.4103/aian.aian_945_22.
Wilcke H, Glaubitz S, Kuck F, Anten C, Liebetanz D, Schmidt J
BMC Neurol. 2023; 23(1):366.
PMID: 37817097
PMC: 10563278.
DOI: 10.1186/s12883-023-03406-0.
Aggelina A, Karampli E, Mavrovounis G, Boutsikos I, Pantazopoulos I, Kakavas S
J Pers Med. 2023; 13(7).
PMID: 37511743
PMC: 10381620.
DOI: 10.3390/jpm13071130.
Mahic M, Bozorg A, DeCourcy J, Golden K, Gibson G, Taylor C
Orphanet J Rare Dis. 2023; 18(1):169.
PMID: 37386469
PMC: 10308674.
DOI: 10.1186/s13023-023-02727-0.
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M
Neurotherapeutics. 2023; 20(2):518-523.
PMID: 36607596
PMC: 10121971.
DOI: 10.1007/s13311-022-01335-3.
Minimal symptom expression achievement over time in generalized myasthenia gravis.
Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kuwabara S
Acta Neurol Belg. 2023; 123(3):979-982.
PMID: 36592291
DOI: 10.1007/s13760-022-02162-1.
Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey.
Mahic M, Bozorg A, DeCourcy J, Golden K, Gibson G, Taylor C
Neurol Ther. 2022; 11(4):1535-1551.
PMID: 35859033
PMC: 9298707.
DOI: 10.1007/s40120-022-00383-3.
Minimal Manifestation Status Indicates a Stable State in Myasthenia Gravis: A Quantitative Study.
Jiang P, Li J, Li H, Zhang B, Yue Y, Wang S
Front Neurol. 2022; 13:880045.
PMID: 35677340
PMC: 9168646.
DOI: 10.3389/fneur.2022.880045.
Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients.
Yu L, Qiu L, Ran H, Ma Q, Lu Y, Liu W
World J Psychiatry. 2022; 12(3):470-482.
PMID: 35433329
PMC: 8968504.
DOI: 10.5498/wjp.v12.i3.470.
Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis.
Su S, Lei L, Fan Z, Zhang S, Wen Q, Wang J
Front Neurol. 2022; 13:816243.
PMID: 35185767
PMC: 8854248.
DOI: 10.3389/fneur.2022.816243.
Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.
Zhang Y, Li F, Zhu H, Yu H, Wang T, Yan X
Neurol Sci. 2022; 43(6):3949-3956.
PMID: 35043357
DOI: 10.1007/s10072-022-05897-0.
Long-term outcomes and prognostic factors in generalized myasthenia gravis.
Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Onishi Y, Oda F
J Neurol. 2021; 268(10):3781-3788.
PMID: 33774750
DOI: 10.1007/s00415-021-10520-x.
Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis.
Thomsen J, Andersen H
Front Neurol. 2021; 11:596382.
PMID: 33424747
PMC: 7793650.
DOI: 10.3389/fneur.2020.596382.
Reappraisal of Oral Steroid Therapy for Myasthenia Gravis.
Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K
Front Neurol. 2020; 11:868.
PMID: 32982912
PMC: 7477376.
DOI: 10.3389/fneur.2020.00868.
Prevalence and Associated Factors of Depressive Symptoms in Patients with Myasthenia Gravis: A Cross-Sectional Study of Two Tertiary Hospitals in Riyadh, Saudi Arabia.
Alanazy M
Behav Neurol. 2019; 2019:9367453.
PMID: 31636730
PMC: 6766166.
DOI: 10.1155/2019/9367453.
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe G, Kaminski H, Aban I, Minisman G, Kuo H, Marx A
Lancet Neurol. 2019; 18(3):259-268.
PMID: 30692052
PMC: 6774753.
DOI: 10.1016/S1474-4422(18)30392-2.
Measuring Clinical Treatment Response in Myasthenia Gravis.
Barnett C, Herbelin L, Dimachkie M, Barohn R
Neurol Clin. 2018; 36(2):339-353.
PMID: 29655453
PMC: 6697147.
DOI: 10.1016/j.ncl.2018.01.006.
Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, Suzuki Y
J Neurol Neurosurg Psychiatry. 2017; 89(5):513-517.
PMID: 29175893
PMC: 5909754.
DOI: 10.1136/jnnp-2017-316625.
Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N
BMJ Open. 2017; 7(2):e013278.
PMID: 28235967
PMC: 5337722.
DOI: 10.1136/bmjopen-2016-013278.